8-K: Evolus Reports Record Q4 and Full Year 2023 Results, Reaffirms 2024 Guidance and Expects Profitability by Late 2024

Evolus announced record fourth quarter and full year 2023 financial results, highlighted by a 40% increase in Q4 revenue and reaffirmed its 2024 revenue guidance, while also projecting profitability by the fourth quarter of 2024.

Summary

• Evolus reported record global net revenue of $61.0 million for the fourth quarter of 2023 and $202.1 million for the full year, representing a 40% and 36% growth over the prior year, respectively.
• The company generated $0.8 million in cash from operating activities in Q4 2023.
• Evolus recorded its lowest non-GAAP operating loss since inception in Q4 2023, at $3.7 million, an improvement of $2 million compared to Q3.
• Full-year 2023 operating expenses were $163.9 million, aligning with the guidance range of $160 million to $165 million.
• The company added more than 840 new accounts purchasing Jeuveau in Q4, a 20% increase above the year-to-date quarterly average.
• Evolus added over 2,900 new accounts in 2023, bringing the total to over 12,400 since launch.
• The reorder rate among customers remains approximately 70%.
• Enrollment in the Evolus Rewards program grew 55% in 2023, reaching approximately 750,000 consumers.
• Repeat treatments represented approximately 60% of total treatments for the quarter, indicating strong brand loyalty.
• Evolus successfully launched Nuceiva in major European markets, including Germany, Austria, and Italy.
• The company expects to achieve profitability for the fourth quarter of 2024 and the full year 2025.
• Evolus is reiterating its full-year net revenue guidance of $255 million to $265 million for 2024, representing 31% growth at the top end of the range.
• The company projects total net revenue to reach at least $700 million by 2028.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to record revenue growth, improved operating performance, and a clear path to profitability. The company's reaffirmation of 2024 guidance and long-term revenue targets further support a positive outlook.

Positives

• Evolus achieved record revenue growth in both Q4 and full-year 2023.
• The company demonstrated significant improvement in operating loss, reaching its lowest non-GAAP operating loss since inception.
• Evolus experienced strong customer acquisition and retention, with a high reorder rate of 70%.
• The Evolus Rewards program saw substantial growth, indicating strong consumer engagement.
• The company is expanding its global footprint with the launch of Nuceiva in key European markets.
• Evolus is on track to achieve profitability by the fourth quarter of 2024 and full year 2025.
• The company's 2024 revenue guidance indicates continued strong growth.
• Evolus has a clear long-term revenue target of at least $700 million by 2028.

Negatives

• The company reported a GAAP loss from operations of $8.6 million for Q4 2023 and $49.2 million for the full year 2023.
• Operating expenses increased in Q4 2023 compared to Q3 2023, including a $4.4 million IPR&D expense related to the European Filler License Agreement.
• The company's cash and cash equivalents increased to $62.8 million by the end of 2023, but this included additional borrowings of $25.0 million.

Risks

• The company's ability to achieve and sustain profitability is dependent on the successful launch and market adoption of its products.
• Evolus faces competition in the aesthetic neurotoxin market.
• The company's future performance is subject to regulatory approvals for new products and indications.
• The company relies on third parties for the development and regulatory approval of its dermal filler products.
• Unfavorable global economic conditions could impact consumer discretionary spending and demand for the company's products.

Future Outlook

Evolus expects total net revenues for the full year 2024 to be between $255 and $265 million, and anticipates achieving profitability for the fourth quarter of 2024 and the full year 2025. The company projects total net revenue to reach at least $700 million by 2028.

Management Comments

• David Moatazedi, President and Chief Executive Officer of Evolus, stated that 2023 was a defining year for Evolus, with record market share as the fastest-growing toxin in the U.S. for the third consecutive year.
• Mr. Moatazedi also mentioned the expansion of their portfolio globally with the addition of an innovative line of facial fillers and continued improvement in operating income performance.
• Management expects to be profitable for the fourth quarter of 2024 and the full year 2025.

Industry Context

Evolus is operating in the competitive aesthetic neurotoxin market, and its growth is driven by its flagship product, Jeuveau. The company's expansion into dermal fillers with Evolysse and Estyme positions it to compete more broadly in the aesthetics market. The company's growth is outpacing the estimated growth rate of the aesthetic neurotoxin market.

Comparison to Industry Standards

• Evolus's 36% revenue growth for 2023 significantly outpaces the overall growth rate of the aesthetic neurotoxin market, indicating strong market share gains.
• The company's focus on a customer-centric approach and digital platform is a differentiator in the market.
• While specific competitor data is not provided, Evolus's claim of being the fastest-growing toxin in the U.S. for three consecutive years suggests a strong competitive position against established players like Allergan (Botox) and Galderma (Dysport).
• The company's expansion into dermal fillers with Evolysse and Estyme is a strategic move to compete with companies like Allergan (Juvederm) and Galderma (Restylane) in the broader aesthetics market.

Stakeholder Impact

• Shareholders are likely to react positively to the strong revenue growth, improved operating performance, and path to profitability.
• Employees may be motivated by the company's success and growth prospects.
• Customers will benefit from the company's expanding product portfolio and continued innovation.
• Suppliers may see increased demand for their products and services as Evolus grows.
• Creditors may view the company's improved financial performance and path to profitability favorably.

Next Steps

• Evolus plans to submit Premarket Approval (PMA) applications for the first two Evolysse dermal filler products with the FDA by mid-year 2024.
• The company expects regulatory approvals for the remaining Estyme dermal filler products in Europe in late 2024.
• Evolus intends to broaden its global footprint by expanding into additional countries with Nuceiva, most notably Australia and Spain, during 2024.

Key Dates

Keywords

Evolus, Jeuveau, Nuceiva, dermal fillers, Evolysse, Estyme, neurotoxin, aesthetics, revenue, profitability, financial results, operating expenses, market share, consumer loyalty, global expansion